Genomic Laboratory, Carlos Chagas Institute, Fiocruz, PR, Curitiba, Brazil.
Laboratory of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Parana, Brazil.
Anticancer Agents Med Chem. 2018;18(15):2070-2077. doi: 10.2174/1871520618666180827102101.
The understanding of cancer has evolved into a complex disease, which has heterogeneous characteristics between different patients, and more than that, a broad range of genetically distinct cells in the same tumor. Chronic and non-transmissible diseases such as cancer have become even more important worldwide and advances in their characterization and properties are running out. In a suitable setting, early diagnosis of cancer and proper treatment are essential to overcome the barriers of tumor healing and quality assurance of the patient's life. The studies included in the analysis were independently retrieved by the authors. The text words included "Non-Small Cell Lung Cancer," "NSCLC," "biomarkers in NSCLC" and "gene in NSCLC"." We were used to perform a systematic literature search in the PubMed and Web of Science databases. There was limit on the start date for published articles (2001), and the search ended in December 2017. For a more comprehensive analysis, articles were only in English.
NON-SMALL CELL LUNG CANCER (NSCLC) MICROENVIRONMENT: This review focuses on lung cancer, especially NSCLC, one of the most worldwide common cancer types, showing the importance of tumor microenvironment in this disease.
This review shows a molecular aspect of NSCLC biomarkers used in clinical approaches, such as EGFR, KRAS, MET, indicating mutations that are crucial for cancer progression and related to treatment properties. We also describe 11 drugs commonly used in cancer treatment that are correlated with the patient genetic profile.
This review highlights the importance of molecular diagnosis of mutations in lung cancer, driving to individualized therapy with the intent of getting a better response to treatment and improving patients' quality of life.
癌症的认识已经发展成为一种复杂的疾病，不同患者之间具有异质性特征，不仅如此，同一肿瘤中还存在广泛的遗传上不同的细胞。癌症等慢性和非传染性疾病在全球范围内变得更加重要，对其特征和性质的研究进展也越来越快。在适当的环境下，早期诊断癌症和适当的治疗对于克服肿瘤愈合的障碍和保证患者的生活质量至关重要。作者独立检索了分析中包含的研究。文本关键词包括“非小细胞肺癌”、“NSCLC”、“NSCLC 中的生物标志物”和“NSCLC 中的基因”。我们习惯于在 PubMed 和 Web of Science 数据库中进行系统的文献检索。发表文章的起始日期有限（2001 年），搜索于 2017 年 12 月结束。为了进行更全面的分析，文章仅使用英文。
非小细胞肺癌（NSCLC）微环境：这篇综述重点介绍了肺癌，特别是 NSCLC，这是全球最常见的癌症类型之一，显示了肿瘤微环境在这种疾病中的重要性。
NSCLC 生物标志物：这篇综述展示了 NSCLC 生物标志物在临床方法中的分子方面，如 EGFR、KRAS、MET，指出了与癌症进展相关的关键突变，并与治疗特性相关。我们还描述了 11 种常用于癌症治疗的药物，这些药物与患者的基因谱相关。
这篇综述强调了肺癌突变的分子诊断的重要性，为个体化治疗提供了指导，旨在获得更好的治疗反应，提高患者的生活质量。
